Biodesix, Inc. (BDSX) Q4 FY25 Earnings Call

Accelerating revenue, 83% gross margins, and first-quarter adjusted EBITDA positivity support continued growth toward profitability.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-01
Length39 minutes
EPS$-0.49
EPS consensus$-1.05
Revenue$21.8M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All BDSX earnings ยท Back to BDSX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.